Louisville Mom Starts Daraxonrasib for Stage IV Pancreatic Cancer as Trial Data Shows 13.2-Month Survival
Updated
Updated · Courier Journal · Aug 13
Louisville Mom Starts Daraxonrasib for Stage IV Pancreatic Cancer as Trial Data Shows 13.2-Month Survival
3 articles · Updated · Courier Journal · Aug 13
Summary
37-year-old Christina Baumer became the first Kentucky patient in July to receive daraxonrasib under FDA compassionate use after her Stage IV pancreatic cancer progressed despite chemotherapy.
Trial results cited by her doctors showed median overall survival of 13.2 months with daraxonrasib versus 6.6 months with chemotherapy alone, while the drug targets the RAS protein long considered “undruggable.”
Baumer was diagnosed in April after scans found pancreatic and liver masses; by mid-June, less than three months into chemotherapy, the tumors had grown again.
Dr. Michael Driscoll said he had prescribed daraxonrasib to seven pancreatic cancer patients by mid-August and was receiving referrals from other Kentucky hospitals as access remains limited outside trials.
The case underscores pancreatic cancer’s grim outlook: more than half of cases are diagnosed at Stage IV, fewer than 1 in 10 patients survive a year, and routine screening tests still do not exist.
Will Stanford's rapid deployment of this experimental therapy set a new, controversial standard for early drug access in oncology?
Could this breakthrough KRAS inhibitor finally turn the tide against one of the world's most deadly and treatment-resistant cancers?
With expanded access bypassing standard wait times, what hidden risks might early adopters face before full FDA approval is granted?
Doubling Survival in Pancreatic Cancer: Daraxonrasib’s Landmark Phase 3 Results, FDA Fast-Track, and the New Era of RAS(ON) Inhibition
Overview
Daraxonrasib, an innovative oral therapy for advanced pancreatic cancer, has achieved remarkable results in clinical trials, nearly doubling patient survival and greatly improving quality of life. Its unique mechanism acts as a molecular glue, blocking cancer growth signals by targeting the active RAS protein, which helps avoid the harsh side effects of chemotherapy. After the FDA accepted its application and fast-tracked its review, daraxonrasib quickly became available to thousands of patients through an expanded access program. Ongoing research is now exploring its use as a first-line treatment, signaling a major shift in cancer care.